LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review

Photo from wikipedia

The objective of this study was to evaluate the evidence on cost‐effectiveness of pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. A systematic review was conducted… Click to show full abstract

The objective of this study was to evaluate the evidence on cost‐effectiveness of pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. A systematic review was conducted using multiple biomedical literature databases from inception to June 2021. Full articles comparing PGx‐guided with nonguided treatment were included for data extraction. Quality of Health Economic Studies (QHES) was used to assess robustness of each study (0–100). Data are reported using descriptive statistics. Of 108 studies evaluating 39 drugs, 77 (71%) showed PGx testing was cost‐effective (CE) (N = 48) or cost‐saving (CS) (N = 29); 21 (20%) were not CE; 10 (9%) were uncertain. Clopidogrel had the most articles (N = 23), of which 22 demonstrated CE or CS, followed by warfarin (N = 16), of which 7 demonstrated CE or CS. Of 26 studies evaluating human leukocyte antigen (HLA) testing for abacavir (N = 8), allopurinol (N = 10), or carbamazepine/phenytoin (N = 8), 15 demonstrated CE or CS. Nine of 11 antidepressant articles demonstrated CE or CS. The median QHES score reflected high‐quality studies (91; range 48–100). Most studies evaluating cost‐effectiveness favored PGx testing. Limited data exist on cost‐effectiveness of preemptive and multigene testing across disease states.

Keywords: drugs clinical; pharmacogenetics implementation; effectiveness pharmacogenetic; cost; clinical pharmacogenetics; cost effectiveness

Journal Title: Clinical Pharmacology and Therapeutics
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.